REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 90.99K shares, a 58.05% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 406.83K shares, a 5100.43% increase year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 72.23K shares, a 68.04% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 255.91K shares, a 573.44% increase year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 825.95K shares, a 69.00% increase from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 488.74K shares, a 499.04% increase from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 81.59K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 90.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | 825.95K shares 10-K · filed 2026-09-24 |
| 2026-03-31 | 406.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-12 | 951.88K shares derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-12-31 | 72.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | 552.88K shares derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-09-30 | 255.91K shares 10-Q · filed 2025-11-06 | 706.65K shares derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-06-30 | 216.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-24 | 488.74K shares 10-K · filed 2026-09-24 |
| 2025-03-31 | 7.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | 348.41K shares derived: sum of 4 quarters · filed 2025-09-17 |
| 2024-12-31 | 226.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | |
| 2024-09-30 | 38.00K shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 76.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | 81.59K shares 10-K · filed 2025-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |